Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company, announced the granting of inducement awards to six new employees on June 1, 2025. The awards, issued under Intellia's 2024 Inducement Plan, consist of time-based restricted stock units (RSUs) for 33,600 shares of common stock. The RSUs will vest in three equal installments on June 1 of 2026, 2027, and 2028, contingent on continued employment. These awards were granted outside the company's stockholder-approved equity incentive plans and were approved by Intellia's compensation committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), un'azienda in fase clinica specializzata nell'editing genico, ha annunciato il 1° giugno 2025 la concessione di premi di incentivo a sei nuovi dipendenti. I premi, assegnati nell'ambito del Piano di Incentivazione 2024 di Intellia, consistono in unità azionarie vincolate (RSU) basate sul tempo per un totale di 33.600 azioni ordinarie. Le RSU matureranno in tre tranche uguali il 1° giugno del 2026, 2027 e 2028, a condizione che il rapporto di lavoro continui. Questi premi sono stati concessi al di fuori dei piani di incentivazione azionaria approvati dagli azionisti e sono stati approvati dal comitato per la remunerazione di Intellia in conformità con la regola Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), una empresa en etapa clínica especializada en edición genética, anunció el 1 de junio de 2025 la concesión de premios de incentivo a seis nuevos empleados. Los premios, otorgados bajo el Plan de Incentivos 2024 de Intellia, consisten en unidades restringidas de acciones (RSU) basadas en tiempo por un total de 33,600 acciones comunes. Las RSU se consolidarán en tres cuotas iguales el 1 de junio de 2026, 2027 y 2028, condicionadas a la continuidad del empleo. Estos premios fueron otorgados fuera de los planes de incentivos accionarios aprobados por los accionistas y fueron aprobados por el comité de compensación de Intellia en cumplimiento con la norma Nasdaq 5635(c)(4).
임상 단계의 유전자 편집 회사인 Intellia Therapeutics(NASDAQ:NTLA)는 2025년 6월 1일 여섯 명의 신규 직원에게 유인 보상을 부여했다고 발표했습니다. 이 보상은 Intellia의 2024년 유인 계획에 따라 발행된 시간 기반 제한 주식 단위(RSU)로, 보통주 33,600주에 해당합니다. RSU는 2026년, 2027년, 2028년 6월 1일에 각각 3등분하여 베스팅되며, 계속 고용 조건이 충족되어야 합니다. 이 보상은 회사 주주 승인 주식 인센티브 계획 외부에서 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 Intellia 보상 위원회의 승인을 받았습니다.
Intellia Therapeutics (NASDAQ:NTLA), une société d'édition génétique en phase clinique, a annoncé le 1er juin 2025 l'attribution de primes d'incitation à six nouveaux employés. Ces primes, délivrées dans le cadre du Plan d'Incitation 2024 d'Intellia, consistent en des unités d'actions restreintes (RSU) basées sur le temps, représentant 33 600 actions ordinaires. Les RSU seront acquises en trois versements égaux les 1er juin 2026, 2027 et 2028, sous réserve de la poursuite de l'emploi. Ces primes ont été accordées en dehors des plans d'incitation en actions approuvés par les actionnaires et ont été validées par le comité de rémunération d'Intellia conformément à la règle Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), ein klinisch fortgeschrittenes Gen-Editing-Unternehmen, gab am 1. Juni 2025 die Gewährung von Anreizprämien an sechs neue Mitarbeiter bekannt. Die Prämien, die im Rahmen des Inducement Plans 2024 von Intellia vergeben wurden, bestehen aus zeitbasierten Restricted Stock Units (RSUs) für insgesamt 33.600 Stammaktien. Die RSUs werden in drei gleichen Raten am 1. Juni 2026, 2027 und 2028 fällig, vorausgesetzt die Beschäftigung besteht weiterhin. Diese Prämien wurden außerhalb der von den Aktionären genehmigten Aktienanreizprogramme gewährt und vom Vergütungsausschuss von Intellia gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
Positive
None.
Negative
None.
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 33,600 shares of Intellia’s common stock, with one-third of such RSUs vesting on June 1, 2026, 2027 and 2028.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
